Grifols instructs Osborne Clarke on €1.7bn Hologic deal

Osborne Clarke acted for Spanish healthcare company Grifols on the €1.7 billion acquisition of Hologic’s blood screening business.


Grifols was also advised by US law firm Proskauer Rose on the deal. Hologic instructed Gibson Dunn & Crutcher, according to Mergermarket.

Under the agreement, Grifols will receive a fully paid-up license to use Hologic’s intellectual property in the blood screening field.  Approximately 175 people, mainly in operations and research and development, will transfer to Grifols, along with Hologic’s blood screening manufacturing facility in Rancho Bernardo, California. 

For the financial year ending in 2017, all of Hologic’s share of its blood screening business was forecast to contribute approximately $240 million of revenue, GAAP diluted earnings per share (EPS) of $0.19, and non-GAAP diluted EPS of $0.34. 

The transaction is expected to be completed in the first quarter of this year, a Hologic statement said.

Grifols instructs Osborne Clarke on €1.7bn Hologic deal

Ben Cook

Iberian Lawyer, is a monthly digital magazine, published by LC Publishing, available in Spanish and English. It represents the main source of information in the legal business sector in Spain and Portugal. The digital magazine – and its portal – address to the protagonists of law firms and in-house lawyers. The magazine is available for free on the website and on Google Play and App Store.

In every issue of the magazine, you will find rankings of lawyers, special report on trends, interviews, information about deals and their advisors.

For further information, please visit the Group’s website

Iberian Legal Group, S.L.
Registered office: C/ Ríos Rosas 44A - 2 G,H 28003 Madrid España

Copyright 2023 © All rights Reserved. Design by Origami Creative Studio


Share on linkedin
Share on twitter
Share on facebook
Share on whatsapp
Share on email
Share on telegram